Genflow Biosciences to Explore Gene Therapy for Pets

LONDON, Sept. 15, 2025 — Genflow Biosciences PLC, a biotech focused on longevity and AAV gene therapy, has signed confidentiality agreements with two major animal health companies to explore how its AAV-based research could be applied to pets. The London-listed company, which is the only publicly quoted company in Europe focused on aging, will share data and hold discussions about potential partnerships.

Genflow’s AAV gene therapy is based on a variant of the SIRT6 gene, which is linked to a longer lifespan in humans who live to more than 100. The company is currently running a trial in beagles, known as the GF-1004 dog aging study, and has reported no safety problems so far with its AAV approach. The talks with the animal health companies are aimed at exploring whether the same technology could be used to extend the healthy lifespan of dogs and other companion animals.

Eric Leire, Genflow’s Chief Executive, stated that the agreements reflect strong industry interest in their longevity platform and their AAV technology. He added that engaging with major animal health players will strengthen the company’s pathway to potential licensing agreements and future commercialization by providing regulatory expertise and sales networks for their products.

This move comes as the pet health market has become a lucrative area for drugmakers, with pet owners increasingly spending more on treatments once reserved for people, including new AAV gene therapies.